Caregen Co., Ltd. (KOSDAQ:214370)

Market Cap	1.94T -36.5%
Revenue (ttm)	74.90B -7.6%
Net Income	22.87B -23.7%
EPS	468.00 -23.5%
Shares Out	48.87M
PE Ratio	79.49
Forward PE	n/a
Dividend	400.00 (1.01%)
Ex-Dividend Date	Jun 29, 2026

Volume	87,861
Open	37,250
Previous Close	37,200
Day's Range	36,000 - 40,950
52-Week Range	36,000 - 153,800
Beta	1.07
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 10, 2026

About Caregen

Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira...

• Industry: Chemicals
• Sector: Materials
• Founded: 2001
• Employees: 209
• Stock Exchange: KOSDAQ
• Ticker Symbol: 214370

Financial Performance

In 2025, Caregen's revenue was 72.81 billion, a decrease of -11.84% compared to the previous year's 82.59 billion. Earnings were 20.10 billion, a decrease of -37.80%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error